François Daviaud, Directeur de la recherche fondamentale du CEA et Bruno Lina, Président d’IDCluster

An IDCluster–CEA Partnership to deploy cutting-edge technologies in the fight against emerging infections

Published on April 13, 2026

Lyon – Paris, April 13, 2026 – Infectious Diseases Cluster, a France 2030 biocluster, and the French Alternative Energies and Atomic Energy Commission (CEA) announce the signing of a strategic partnership aimed at strengthening scientific and technological collaboration in the fight against emerging infectious diseases and antimicrobial resistance.

The CEA thus becomes a key technology partner of IDCluster, helping to strengthen the scientific and technological expertise available to support projects backed by the biocluster.

This partnership leverages the complementary expertise of both organizations to accelerate the development of innovative projects, facilitate access to cutting-edge scientific infrastructure, and strengthen the French research and innovation ecosystem in these priority public health areas.

Scientific and technological collaboration to support innovation projects

As part of this partnership, the CEA will make its scientific expertise and technological platforms available to project leaders supported by IDCluster in order to enhance the scientific and technological value of the projects under development.

The expertise provided by the CEA will cover IDCluster’s four major scientific programs:

  • Epidemiological surveillance: detection of pathogens in the environment, metagenomics, high-throughput sequencing, high-performance computing.
  • Diagnostics: rapid “point-of-care” diagnostic technologies, identification of resistant bacteria, microfluidics, instrumentation, and multimodal imaging.
  • Prevention: development and evaluation of preventive and vaccine solutions, molecular characterization, cryomicroscopy, vaccine formulation, and monitoring of bioproductions.
  • Therapeutics: development and evaluation of therapeutic solutions, mass spectrometry, nanovectorization, and pharmacokinetic and pharmacodynamic studies using in vivo imaging.

Access to the CEA’s Magellan program to support deep tech entrepreneurship

The partnership also gives IDCluster project leaders the opportunity, when eligible, to benefit from the CEA’s Magellan program, dedicated to supporting the creation of research-based deep tech startups.

The combined support from IDCluster, CEA, and Magellan will thus help bolster the credibility of these projects among investors and accelerate their transition from scientific innovation to business creation.

Finally, this partnership also includes collaboration on the “ID360 Scientific and Economic Intelligence Platform” project led by IDCluster, with the shared goal of pooling the scientific and technological data from this platform.

← Previous